Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,009 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

NCT02651662

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Johns Hopkins University Baltimore, Maryland, United States
  • Dana Farber/Harvard Cancer Center - PO box 849168 Boston, Massachusetts, United States
  • Harvard Medical School - Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Cancer & Hematology Centers of Western Michigan Grand Rapids, Michigan, United States
View all 30 locations
View Trial Details
Completed

The Role of 18F-FDG-PET for Staging and Prognostication

NCT04600804

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Ematologia Ospedale Vito Fazzi Lecce, Apulia, Italy
  • U.O.C Ematologia e Trapianto A.O. C. Panico Tricase, Apulia, Italy
  • U.O.Ematologia Ospedale Guglielmo da Saliceto Piacenza, Emilia-Romagna, Italy
  • Ematologia Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova Reggio Emilia, Emilia-Romagna, Italy
View all 34 locations
View Trial Details
Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

NCT02220985

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, +57 more
Locations
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

NCT06113081

Conditions
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome, +17 more
Locations
  • Clinica di Ematologia - AOU Ospedali Riuniti delle Marche Ancona, Italy
  • S.C. Ematologia e Trapianto emopoietico - A.O. S.Giuseppe Moscati Avellino, Italy
  • Clinica Dermatologia - A.O.U. Policlinico Consorziale Bari, Italy
  • U.O.C. Ematologia - IRCCS Istituto Tumori Giovanni Paolo II Bari, Italy
View all 21 locations
View Trial Details
Completed

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

NCT03106324

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Innsbruck University Hospital Innsbruck, Austria
  • LKH Hochsteiermark Leoben, Austria
  • University hospital St. Pölten Pölten, Austria
  • CHU Saint-Pierre Brussels, Belgium
View all 125 locations
View Trial Details
Completed

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

NCT05144841

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) Orange, California, United States
  • Innovative Clinical Research Institute ( Site 0202) Whittier, California, United States
  • Georgetown University Medical Center ( Site 0204) Washington D.C., District of Columbia, United States
  • Northside Hospital ( Site 0206) Atlanta, Georgia, United States
View all 71 locations
View Trial Details

Related conditions